MARKET

IPHA

IPHA

Innate Pharma Sa
NASDAQ
1.890
-0.020
-1.05%
After Hours: 1.880 -0.01 -0.53% 17:47 12/05 EST
OPEN
1.880
PREV CLOSE
1.910
HIGH
1.960
LOW
1.880
VOLUME
12.67K
TURNOVER
--
52 WEEK HIGH
3.511
52 WEEK LOW
1.410
MARKET CAP
174.23M
P/E (TTM)
-2.9221
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IPHA last week (1124-1128)?
Weekly Report · 6d ago
Innate Pharma Reports Updated Share and Voting Rights Totals
Reuters · 11/28 06:00
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
Barchart · 11/28 00:00
Weekly Report: what happened at IPHA last week (1117-1121)?
Weekly Report · 11/24 09:10
Weekly Report: what happened at IPHA last week (1110-1114)?
Weekly Report · 11/17 09:10
Innate Pharma SA to Present at Jefferies Global Healthcare Conference
Reuters · 11/17 06:00
Innate Pharma reports 9M results
Seeking Alpha · 11/13 11:32
Innate Pharma Reports €56.4M Cash And €2.3M Nine-Month Revenue As Lacutamab Advances Toward TELLOMAK-3 Phase 3 Initiation In 2026
Benzinga · 11/13 06:18
More
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Webull offers Innate Pharma SA (ADR) stock information, including NASDAQ: IPHA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPHA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPHA stock methods without spending real money on the virtual paper trading platform.